---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-061344"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:18:19.295669+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# KalVista appoints Benjamin Palleiko as CEO; Crockett resigns in planned transition

## Summary
- T. Andrew Crockett resigned as CEO and board director effective March 6, 2024, not due to any disagreement.
- Benjamin L. Palleiko appointed CEO and to the Board; he was President/CBO/CFO and remains principal financial officer.
- Palleiko receives base salary of $661,800/year, 60% bonus target, and 250,000 RSUs vesting quarterly over 4 years.
- Crockett separation includes 18 months base salary lump sum, full FY2024 target bonus, and 150,000 RSU/PSU acceleration.
- Sebetralstat NDA filing on track for H1 2024 in US; Europe and Japan filings in H2 2024 after positive Phase 3 trial.

## SEC filing metadata
- accession: 0001193125-24-061344
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000119312524061344/0001193125-24-061344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000119312524061344/d808049d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-061344
- JSON: https://secwatch.observer/filing/0001193125-24-061344.json
- Plain text: https://secwatch.observer/filing/0001193125-24-061344.txt

## Key facts
- Executive change
  T. Andrew Crockett resigned as Chief Executive Officer at KalVista Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: On March 6, 2024, T. Andrew Crockett announced his resignation from his position as the Chief Executive Officer and from his position on the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000119312524061344/0001193125-24-061344-index.htm
- Executive change
  Benjamin L. Palleiko was appointed as Chief Executive Officer at KalVista Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: Effective March 6, 2023, the Board of Directors (the “ Board ”) of KalVista Pharmaceuticals, Inc. (the “ Company ”) appointed Benjamin L. Palleiko, the Company’s President, Chief Business Officer and Chief Financial Officer, as its Chief Executive Officer and principal executive officer and he will remain the principal financial officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000119312524061344/0001193125-24-061344-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.